Illumina (NASDAQ:ILMN) Reaches New 12-Month High – Time to Buy?

Shares of Illumina, Inc. (NASDAQ:ILMN) hit a new 52-week high during trading on Tuesday . The stock traded as high as $195.09 and last traded at $194.33, with a volume of 2102097 shares traded. The stock had previously closed at $188.68.

More Illumina News

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Illumina beat revenue estimates with quarterly sales of $1.09 billion, up 4.8% year over year, and raised its full-year EPS outlook, which signals better-than-expected business performance and improving profitability. Illumina (ILMN) Is Up 9.1% After Raising EPS Outlook On Revenue Beat Has The Bull Case Changed?
• Positive Sentiment: Management said Illumina is making progress on key priorities and highlighted the strength of its sequencing ecosystem, supporting the bullish case that the company can sustain growth even as competition increases. Illumina (ILMN) Jumps On Earnings And Guidance As Valuation Questions Remain
• Positive Sentiment: Illumina’s shares reached a 52-week high, reflecting strong recent momentum and renewed investor optimism after the earnings-driven reassessment of the stock. Illumina, Inc. (ILMN) Hit a 52 Week High, Can the Run Continue?
• Neutral Sentiment: New coverage comparing Illumina with Exelixis frames ILMN as a value-stock candidate, but this appears to be a valuation discussion rather than a direct operating catalyst. EXEL vs. ILMN: Which Stock Is the Better Value Option?
• Neutral Sentiment: Illumina also announced a supply agreement with Bifrost Biosystems, which expands use of its sequencing chemistry but is unlikely to move the stock as much as the earnings beat and guidance raise. Bifrost Biosystems Pens Agreement with Illumina for Supply of Sequencing Chemistry for Optical Pooled Screening Platform

Analysts Set New Price Targets

A number of equities research analysts have commented on ILMN shares. Canaccord Genuity Group reduced their price objective on Illumina from $150.00 to $140.00 and set a “hold” rating for the company in a research note on Friday, May 1st. Evercore reaffirmed an “outperform” rating on shares of Illumina in a research report on Monday. Weiss Ratings upgraded Illumina from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, June 3rd. Guggenheim raised their target price on Illumina from $180.00 to $200.00 and gave the company a “buy” rating in a research report on Monday, June 29th. Finally, JPMorgan Chase & Co. upgraded shares of Illumina from a “neutral” rating to an “overweight” rating and raised their price target for the stock from $125.00 to $185.00 in a research note on Wednesday, June 10th. Eight research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, Illumina currently has a consensus rating of “Hold” and a consensus target price of $148.94.

Illumina Stock Down 2.1%

The company has a current ratio of 1.75, a quick ratio of 1.36 and a debt-to-equity ratio of 0.56. The firm has a market cap of $28.42 billion, a P/E ratio of 34.15, a price-to-earnings-growth ratio of 3.59 and a beta of 1.47. The stock’s fifty day moving average is $158.58 and its two-hundred day moving average is $140.74.

Illumina (NASDAQ:ILMN) last posted its earnings results on Thursday, April 30th. The life sciences company reported $1.15 EPS for the quarter, topping the consensus estimate of $1.05 by $0.10. Illumina had a return on equity of 31.01% and a net margin of 19.42%.The business had revenue of $1.09 billion during the quarter, compared to analysts’ expectations of $1.07 billion. During the same period in the previous year, the business earned $0.97 earnings per share. The firm’s revenue was up 4.8% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. As a group, research analysts anticipate that Illumina, Inc. will post 5.21 earnings per share for the current year.

Insider Activity at Illumina

In other Illumina news, SVP Patricia Leckman sold 783 shares of the company’s stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $162.59, for a total value of $127,307.97. Following the completion of the sale, the senior vice president owned 21,259 shares of the company’s stock, valued at $3,456,500.81. This represents a 3.55% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Scott M. Davies sold 615 shares of the company’s stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $180.00, for a total transaction of $110,700.00. Following the completion of the sale, the insider directly owned 20,953 shares of the company’s stock, valued at $3,771,540. This trade represents a 2.85% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 1,003,769 shares of company stock valued at $155,710,908. 2.90% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Illumina

Several institutional investors have recently bought and sold shares of the stock. Elyxium Wealth LLC purchased a new stake in shares of Illumina during the fourth quarter valued at approximately $25,000. Board of the Pension Protection Fund purchased a new position in shares of Illumina during the fourth quarter valued at approximately $26,000. Creative Capital Management Investments LLC increased its position in Illumina by 160.0% during the 4th quarter. Creative Capital Management Investments LLC now owns 195 shares of the life sciences company’s stock valued at $26,000 after purchasing an additional 120 shares during the period. TD Waterhouse Canada Inc. bought a new position in Illumina in the fourth quarter worth about $26,000. Finally, Laurel Wealth Advisors LLC bought a new position in shares of Illumina in the 4th quarter worth approximately $26,000. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.